

[全部](#)[图片](#)[新闻](#)[视频](#)[购物](#)[更多](#)[设置](#)[工具](#)

找到约 249,000 条结果 (用时 0.54 秒)

Google 学术: Emerging Therapies in Cholestatic Liver Disease

... liver histology in primary biliary cirrhosis: a three-year ... - Rautiainen - 被引用次数: 243

Liver fibrosis - Bataller - 被引用次数: 4501

... emerging therapies in nonalcoholic fatty liver disease - Kashi - 被引用次数: 96

Novel and emerging therapies for cholestatic liver diseases. - NCBI

<https://www.ncbi.nlm.nih.gov/pubmed/29758112> - 翻译此页

作者: J Goldstein - 2018 - 被引用次数: 2 - 相关文章

Liver Int. 2018 Sep;38(9):1520-1535. doi: 10.1111/liv.13880. Epub 2018 Jun 14. Novel and emerging therapies for cholestatic liver diseases. Goldstein J(1) ...

Cholestatic liver diseases: new targets, new therapies - NCBI - NIH

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6109852/> - 翻译此页

作者: P Santiago - 2018

2018年8月24日 - Primary sclerosing cholangitis (PSC) is a challenging, idiopathic cholestatic liver disease marked by chronic and progressive biliary inflammation, bile duct stricturing and fibrosis. ...

As of today, treatment for PSC is limited and liver transplantation is the only intervention shown to prolong survival.

(PDF) Cholestatic liver diseases: new targets, new therapies

https://www.researchgate.net/.../327204814_Cholestatic_liver_diseases_new_... - 翻译此页

2018年10月27日 - Cholestatic liver diseases: new targets, new therapies. Cholestatic liver diseases result from gradual destruction of bile ducts, accumulation of bile acids and self-perpetuation of the inflammatory process leading to damage to cholangiocytes and hepatocytes.

Update on pharmacotherapies for cholestatic liver disease - Ali - 2017

...

<https://aasldpubs.onlinelibrary.wiley.com/doi/full/10.1002/hep4.1013> - 翻译此页

作者: AH Ali - 2017 - 被引用次数: 5 - 相关文章

跳到 Established and Emerging Therapies for PBC and PSC - Therapies (Established or Undergoing

Match Overview

1	Crossref 117 words Ulrich Beuers, Michael Trauner, Peter Jansen, Raoul Po upon. "New paradigms in the treatment of hepatic chol ...	3%
2	Crossref 93 words Claudia D. Fuchs, Emina Halilbasic, Michael Trauner. "N ovel treatments targeting metabolic and signaling mec ...	2%
3	Crossref 80 words Elsemieke de Vries, Ulrich Beuers. "Management of cho lestatic disease in 2017", Liver International, 2017	2%
4	Crossref 60 words Amardeep Khanna, David E. Jones. "Novel strategies an d therapeutic options for the management of primary b ...	1%
5	Crossref 46 words Martin Wagner, Gernot Zollner, Michael Trauner. "New f ... olecular insights into the mechanisms of cholestasis", J	1%
6	Internet 41 words crawled on 13-Feb-2018 www.thieme-connect.de	1%
7	Crossref 38 words James L. Boyer. "Treatment of chronic cholestasis: Wh ... we know and what we will know?", Clinical Liver Disease	1%
8	Internet 34 words crawled on 17-Feb-2019 angiogenesis-blog.com	1%
9	Crossref 27 words James M. Crawford, Paulette Bioulac-Sage, Prodromo ... Hytioglou. "Structure, Function, and Responses to Injury	1%
10	Internet 21 words crawled on 07-Dec-2015 www.ncbi.nlm.nih.gov	1%
11	Crossref 19 words Christophe Corpechot. "Primary biliary cirrhosis and bi ... acids", Clinics and Research in Hepatology and Gastroe	<1%

Name of Journal: *World Journal of Clinical Cases*

Manuscript NO: 45306

Manuscript Type: MINIREVIEWS

Cholestatic liver diseases: An era of emerging therapies

Samant H *et al.* Cholestatic liver disease

Hrishikesh Samant, Wuttiorn Manatsathit, David Dies, Hosein Shokouh-Amiri, Gazi
Zibari, Moheb Boktor, Jonathan Steve Alexander

Abstract

Recently the field of cholestasis has expanded enormously reflecting an improved
understanding of the molecular mechanisms underlying bile secretion and its



All

Images

Videos

翻译成中文

关闭取词

255,000 Results

Any time ▾

Cholestatic Liver Diseases: Emerging Treatment Options ...

<https://checkrare.com/cholestatic-liver-diseases-emerging-treatment-options> ▾

Ron Cooper, President and CEO of Albireo, provides an overview of Cholestatic liver diseases. Cholestasis is a chronic condition resulting from an impairment of the biliary system, that provokes a decrease or interruption of bile secretion from the liver to the intestine, leading to the degeneration of liver tissues, **chronic inflammation** and the formation of scar tissue (fibrosis).

Cholestatic and Autoimmune Liver Diseases | AASLD

<https://www.aasld.org/membership/SIGs/cholestatic-liver-disorders-0> ▾

The Cholestatic and Autoimmune Liver Diseases Special Interest Group (SIG) is an international community of investigators and practitioner focusing on preventing diagnosing and **treating cholestatic liver diseases**, as well as **diseases of the biliary tree (choangiopathies)**.

Novel and emerging therapies for cholestatic liver diseases

https://www.researchgate.net/publication/325133843_Novel_and_emerging_therapies_for...

Primary **sclerosing cholangitis (PSC)** is a **chronic, immune-mediated cholestatic liver disease** that often progresses to secondary **biliary cirrhosis** and **end-stage liver disease**.

Novel and emerging therapies for cholestatic liver diseases

<https://miami.pure.elsevier.com/en/publications/novel-and-emerging-therapies-for...> ▾

T1 - Novel and emerging therapies for cholestatic liver diseases. AU - Goldstein, Jordan. AU - Levy, Cynthia. PY - 2018/9/1. Y1 - 2018/9/1. N2 - While **bile acids** are important for both digestion and signalling, hydrophobic bile acids can be harmful, especially when in high concentrations.

Cited by: 3

Author: Jordan Goldstein, Cynthia Levy

Publish Year: 2018

Novel and emerging therapies for cholestatic liver diseases

<https://onlinelibrary.wiley.com/doi/full/10.1111/liv.13880>

May 14, 2018 - Many novel therapies targeting nuclear and surface receptors involved in **bile acid** signalling are currently under evaluation for cholestatic liver diseases, including **agonists of FXR, PPAR, PXR and TGR5**, among others, with promising results.

Cited by: 3

Author: Jordan Goldstein, Cynthia Levy

Publish Year: 2018

Novel and emerging therapies for cholestatic liver diseases

<https://onlinelibrary.wiley.com/doi/abs/10.1111/liv.13880>

This review summarizes our current understanding of the role of bile acids in the pathophysiology of **cholestatic liver diseases**, presents the rationale for already approved medical **therapies** and discusses novel pharmacologic **therapies** under investigation.

Cited by: 3

Author: Jordan Goldstein, Cynthia Levy

Publish Year: 2018